NYSE:PRGOPharmaceuticals
How Perrigo’s Steady 2026 Outlook Amid Soft Sales At Perrigo (PRGO) Has Changed Its Investment Story
Perrigo recently reported past first-quarter 2026 results with adjusted earnings per share above estimates but revenue below expectations, citing softer consumer demand and inventory destocking, while it reaffirmed its full-year 2026 guidance.
An interesting aspect is that management kept its outlook intact despite weaker sales trends and broadly lower analyst estimates, underscoring confidence in its current plan.
We’ll now assess how Perrigo’s decision to reaffirm full-year guidance...